Search

GlaxoSmithKline PLC

Aperta

SettoreSettore sanitario

1,841 1.13

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1816

Massimo

1858.5

Metriche Chiave

By Trading Economics

Entrata

498M

2.1B

Vendite

561M

8.5B

P/E

Media del settore

13.748

90.422

EPS

0.55

Rendimento da dividendi

3.55

Margine di Profitto

25.085

Dipendenti

68,629

EBITDA

129M

3.4B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-0.02% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.55%

2.13%

Utili prossimi

4 feb 2026

Prossima data del Dividendo

9 apr 2026

Prossima data del' Ex Dividendo

19 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.1B

74B

Apertura precedente

1839.87

Chiusura precedente

1841

Notizie sul Sentiment di mercato

By Acuity

36%

64%

106 / 352 Classifica in Healthcare

GlaxoSmithKline PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 gen 2026, 11:34 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

RAPT Therapeutics Shares Jump Following Acquisition by GSK

20 gen 2026, 10:40 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 gen 2026, 07:47 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

22 dic 2025, 11:55 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics Boosts U.S. Presence With $280 Million GSK Facility Deal

20 gen 2026, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 gen 2026, 14:53 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 gen 2026, 13:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

GSK's RAPT Deal Helps Address Looming Drug Patent Cliff -- Market Talk

20 gen 2026, 13:28 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

GSK's Deal to Buy RAPT Is the Right Risk -- Market Talk

20 gen 2026, 12:10 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 gen 2026, 07:15 UTC

Acquisizioni, Fusioni, Takeovers

GSK Expects to Complete RAPT Buy in 1Q

20 gen 2026, 07:15 UTC

Acquisizioni, Fusioni, Takeovers

GSK: RAPT Buy Subject to Customary Closing Conditions

20 gen 2026, 07:14 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Launch Tender Offer to Buy RAPT Common Stock Within 10 Business Days

20 gen 2026, 07:14 UTC

Acquisizioni, Fusioni, Takeovers

GSK: Ozureprubart Rights Exclude Mainland China, Macau, Taiwan, Hong Kong

20 gen 2026, 07:13 UTC

Acquisizioni, Fusioni, Takeovers

GSK Gets Global Rights to the Ozureprubart Program Under RAPT Deal

20 gen 2026, 07:13 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20 gen 2026, 07:13 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC to Get Special Div of $0.250B

20 gen 2026, 07:08 UTC

Acquisizioni, Fusioni, Takeovers

GSK Estimated Upfront Investment Is $1.9B

20 gen 2026, 07:08 UTC

Acquisizioni, Fusioni, Takeovers

GSK Offering RAPT Therapeutics Hldrs $58.00 Per Shr

20 gen 2026, 07:07 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC to Buy RAPT Therapeutics for $2.2 Billion

20 gen 2026, 07:06 UTC

Acquisizioni, Fusioni, Takeovers

GSK PLC to Buy RAPT Therapeutics

20 gen 2026, 00:21 UTC

Acquisizioni, Fusioni, Takeovers

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

16 gen 2026, 17:03 UTC

Discorsi di Mercato

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

30 dic 2025, 08:45 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk

22 dic 2025, 11:40 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics Boosts U.S. Presence With $280M GSK Facility Deal

22 dic 2025, 11:39 UTC

Discorsi di Mercato

U.S. Pressure Clouds GSK's Outlook -- Market Talk

22 dic 2025, 00:16 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Plan Additional Investment to Expand Production Capacity

22 dic 2025, 00:15 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: To Acquire Full Stake in GSK-Owned Human Genome Sciences in Rockville, Md.

22 dic 2025, 00:15 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics to Buy U.S. Drug Production Facility From GSK for $280M

21 nov 2025, 12:28 UTC

Discorsi di Mercato

GSK Unlikely to Face Material Impact from AnaptysBio Litigation -- Market Talk

6 nov 2025, 16:16 UTC

Utili

Moderna's Quarter Wasn't As Bad as It Could Have Been. The Stock is Up -- Barrons.com

GlaxoSmithKline PLC Previsione

Obiettivo di Prezzo

By TipRanks

-0.02% in calo

Previsioni per 12 mesi

Media 1,817.08 GBX  -0.02%

Alto 2,250 GBX

Basso 1,500 GBX

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per GlaxoSmithKline PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

15 ratings

3

Acquista

8

Mantieni

4

Vendi

Sentiment

By Acuity

106 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat